Anika Therapeutics Inc. (NASDAQ:ANIK) management will conduct a conference call for 4th November 2020 at 5:00 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.anikatherapeutics.com
Earnings Expectation
Anika Therapeutics Inc. is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.01 per share from revenue of $ 30.11 million. Looking ahead, the full year loss are expected at $ 0.22 per share on the revenues of $ 130.94 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 160.00 million ~ $ 165.00 million
Click Here For More Historical Outlooks Of Anika Therapeutics Inc.
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.
